SciELO - Scientific Electronic Library Online

 
vol.24 número2Hipertrigliceridemia: clasificación, riesgo cardiovascular y conducta terapéuticaPapel de los lípidos y las lipoproteínas en la aterosclerosis índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Correo Científico Médico

versión On-line ISSN 1560-4381

Resumen

OJEDA ARMAS, Iliana et al. New therapeutic approaches to dyslipidemias. ccm [online]. 2020, vol.24, n.2, pp.702-722.  Epub 01-Jun-2020. ISSN 1560-4381.

Dyslipidemia is a major modifiable risk factor for cardiovascular disease due to atherosclerosis. A literature review was conducted with the descriptors dyslipidemia and treatment, in English and Spanish, in PubMed, PubMed Central, SciELO and Clinical Key. Emphasis was placed on new therapeutic modalities approved or under development that act mainly on molecular targets: subtilisin/kexin type 9 paraprotein converter (PCSK9), cholesterol ester transfer protein (CETP), angiopoietin-like protein 3 (ANGPTL3), receptor activated by peroxisome alpha proliferator (PPARα), acetyl-CoA carboxylase, ATP citrate lyase, diacylglycerol acyltransferase, apo A1, apo C-III, apo (a) and microsomal triglyceride transfer protein (MTP). The key therapeutic modalities were monoclonal antibodies (alirocumab and evolocumab), no-sense oligonucleotides (inclisiran, volanesorsen), vaccines, genome editing, enzyme inhibitors (gemcaben, prodigastat) and nutritional supplements (omega 3).

Palabras clave : dyslipidemias; hypercholesterolemia; hypertriglyceridemia; low HDL-cholesterol; cardiovascular disease; prevention; lipid-lowering therapy.

        · resumen en Español     · texto en Español     · Español ( pdf )